New research offers fresh evidence that a single digital
therapeutics platform can improve outcomes for commonly
co-occurring conditions
NEW
YORK, April 27, 2022 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics
(DTx) market, announced the publication of a retrospective,
real-world study demonstrating the impact of managing diabetes and
weight together on a single digital platform at the Advanced
Technologies and Treatments for Diabetes (ATTD) Conference being
held April 27th –
30th in Barcelona and
online.
To better understand the impact of an integrated,
multi-condition digital therapeutics platform, Dario analyzed 12
months of real-world retrospective data for a group of 715
individuals using the Dario app to manage their blood sugar and
demonstrating a Body Mass Index (BMI) of greater than 30
kg/m2, the clinical baseline for obesity.
The study found that nearly two thirds of Dario participants
with a BMI of more than 30 reduced their BMI by an average of 2.8
units with an average weight loss of 7.4% (p≤0.05).
In addition, the study also examined a subgroup of Dario
participants with BMIs greater than 30 and high-risk blood glucose
readings of more than 180 mg/dL to understand the impact on both
diabetes and weight management. This subgroup also demonstrated
improved clinical outcomes, reducing their weight by an average of
4.9% and reducing their average blood glucose by 16.1% over a
12-months period.
For people living with diabetes, obesity is well-known as a
costly and complicating risk factor. Research has shown that
compared to people living without diabetes, people living with the
condition have a harder time losing weight and sustaining weight
loss. Dario's single digital therapeutics platform is designed to
address multiple chronic conditions with holistic, person-centered
care by making it easy for people to change their behaviors for
lasting results.
"I am proud to share new evidence that Dario's approach to
providing user-centric support for common, co-occurring chronic
conditions can make a significant difference for the people we
help. This research, combined with our previous study showing
improvements in overall health for people living with diabetes and
high blood pressure, offer a compelling argument for digital
solutions that prioritize a whole health experience," said Yifat
Hershcovitz, PhD., Scientific and Clinical Director at DarioHealth
and supervisor of the study.
"Dario's integrated whole health approach to chronic condition
management offers a stark contrast to traditional point solutions,
and research is crucial to help communicate the value of our
solution. I'm very excited to publish our second set of results
evaluating multi-condition outcomes, and to show once again that
our impact is significant and sustainable because we are making it
easy for the people we serve to change their behaviors with a
simple, unified experience," said Omar
Manejwala, MD, Chief Medical Officer at
DarioHealth.
For more information about ATTD or to register for access to the
study, please visit the conference website at
https://attd.kenes.com.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital
therapeutics company revolutionizing how people with chronic
conditions manage their health. DarioHealth offers one of the most
comprehensive digital therapeutics solutions on the market -
covering multiple chronic conditions including diabetes,
hypertension, weight management, musculoskeletal and behavioral
health within one integrated technology platform.
Dario's next-generation, AI-powered, digital therapeutic
platform supports more than just an individual's disease. Dario
provides adaptive, personalized experiences that drive behavior
change through evidence-based interventions, intuitive, clinically
proven digital tools, high-quality software, and coaching to help
individuals improve health and sustain meaningful outcomes.
Dario's unique user-centric approach to product design and
engagement creates an unparalleled experience that is highly rated
by users and delivers sustainable results.
The company's cross-functional team operates at the intersection
of life sciences, behavioral science, and software technology and
utilizes a performance-based approach to improve its users'
health.
On the path to better health, Dario makes the right thing to do
the easy thing to do. To learn more about DarioHealth and its
digital health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the improvements of conditions patients experienced while using its
digital therapeutic platform and that the study offers a compelling
argument for digital solutions that prioritize a whole health
experience. Without limiting the generality of the foregoing, words
such as "plan," "project," "potential," "seek," "may," "will,"
"expect," "believe," "anticipate," "intend," "could," "estimate" or
"continue" are intended to identify forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario™
as described herein) may differ significantly from those set forth
in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Media Contact:
Josephine
Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262
View original
content:https://www.prnewswire.com/news-releases/dariohealth-presents-new-clinical-research-demonstrating-improved-outcomes-for-participants-using-a-single-integrated-digital-solution-to-manage-multiple-chronic-conditions-301534177.html
SOURCE DarioHealth Corp.